Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 10,876

Sort by:

Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021

US$ 2,000.00

Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 SUMMARY Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 provides an...

April 2021 45 pages

Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 SUMMARY Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Acute...

April 2021 35 pages

Addiction (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Addiction (Central Nervous System) - Drugs in Development, 2021 SUMMARY Addiction (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Addiction pipeline landscape. The re...

April 2021 45 pages

Adenocarcinoma Of The Gastroesophageal Junction (Oncology) - Drugs in Development, 2021

US$ 2,500.00

Adenocarcinoma Of The Gastroesophageal Junction (Oncology) - Drugs in Development, 2021 SUMMARY Adenocarcinoma Of The Gastroesophageal Junction (Oncology) - Drugs in Development, 2021 provides an over...

April 2021 260 pages

Adenocarcinoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Adenocarcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Adenocarcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Adenocarcinoma pipeline landscape. The report provides...

April 2021 100 pages

Adenoid Cystic Carcinoma (ACC) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Adenoid Cystic Carcinoma (ACC) (Oncology) - Drugs in Development, 2021 SUMMARY Adenoid Cystic Carcinoma (ACC) (Oncology) - Drugs in Development, 2021 provides an overview of the Adenoid Cystic Carcino...

April 2021 60 pages

Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31) - Drugs in Development, 2021

US$ 3,000.00

Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31) - Drugs in Development, 2021 SUMMARY Adenosine Monophosphate Activated P...

April 2021 120 pages

Adenosine Receptor A1 (ADORA1) - Drugs in Development, 2021

US$ 3,000.00

Adenosine Receptor A1 (ADORA1) - Drugs in Development, 2021 SUMMARY Adenosine Receptor A1 (ADORA1) - Drugs in Development, 2021 provides in depth analysis on Adenosine Receptor A1 (ADORA1) targeted pi...

April 2021 45 pages

Adenosine Receptor A2a (ADORA2A) - Drugs in Development, 2021

US$ 3,000.00

Adenosine Receptor A2a (ADORA2A) - Drugs in Development, 2021 SUMMARY Adenosine Receptor A2a (ADORA2A) - Drugs in Development, 2021 provides in depth analysis on Adenosine Receptor A2a (ADORA2A) targe...

April 2021 90 pages

Adenoviridae Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Adenoviridae Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Adenoviridae Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Adenoviridae Inf...

April 2021 55 pages

Adiponectin Receptor Protein 1 (Progestin And AdipoQ Receptor Family Member I or ADIPOR1) - Drugs in Development, 2021

US$ 3,000.00

Adiponectin Receptor Protein 1 (Progestin And AdipoQ Receptor Family Member I or ADIPOR1) - Drugs in Development, 2021 SUMMARY Adiponectin Receptor Protein 1 (Progestin And AdipoQ Receptor Family Memb...

April 2021 35 pages

ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2' Phospho ADP Ribosyl Cyclase/2' Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20) - Drugs in Development, 2021

US$ 3,000.00

ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2' Phospho ADP Ribosyl Cyclase/2' Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or E...

April 2021 50 pages

ADP Ribosylation Factor 6 (ARF6) - Drugs in Development, 2021

US$ 3,000.00

ADP Ribosylation Factor 6 (ARF6) - Drugs in Development, 2021 SUMMARY ADP Ribosylation Factor 6 (ARF6) - Drugs in Development, 2021 provides in depth analysis on ADP Ribosylation Factor 6 (ARF6) targe...

April 2021 30 pages

Adrenal Gland Cancer (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Adrenal Gland Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Adrenal Gland Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Adrenal Gland Cancer pipeline landscape. T...

April 2021 30 pages

Ageing (Other Diseases) - Drugs in Development, 2021

US$ 2,000.00

Ageing (Other Diseases) - Drugs in Development, 2021 SUMMARY Ageing (Other Diseases) - Drugs in Development, 2021 provides an overview of the Ageing pipeline landscape. The report provides comprehensi...

April 2021 105 pages

Aicardi-Goutieres Syndrome (AGS) (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Aicardi-Goutieres Syndrome (AGS) (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Aicardi-Goutieres Syndrome (AGS) (Genetic Disorders) - Drugs in Development, 2021 provides an overview of the...

April 2021 30 pages

Alcoholic Fatty Liver Disease (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Alcoholic Fatty Liver Disease (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Alcoholic Fatty Liver Disease (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Alcoholi...

April 2021 30 pages

Aldehyde Dehydrogenase Mitochondrial (ALDH Class 2 or ALDH E2 or ALDHI or ALDH2 or EC 1.2.1.3) - Drugs in Development, 2021

US$ 3,000.00

Aldehyde Dehydrogenase Mitochondrial (ALDH Class 2 or ALDH E2 or ALDHI or ALDH2 or EC 1.2.1.3) - Drugs in Development, 2021 SUMMARY Aldehyde Dehydrogenase Mitochondrial (ALDH Class 2 or ALDH E2 or ALD...

April 2021 35 pages

Aldose Reductase (Aldehyde Reductase or Aldo Keto Reductase Family 1 Member B1 or AKR1B1 or EC 1.1.1.21) - Drugs in Development, 2021

US$ 3,000.00

Aldose Reductase (Aldehyde Reductase or Aldo Keto Reductase Family 1 Member B1 or AKR1B1 or EC 1.1.1.21) - Drugs in Development, 2021 SUMMARY Aldose Reductase (Aldehyde Reductase or Aldo Keto Reductas...

April 2021 35 pages

ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021

US$ 3,000.00

ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 SUMMARY ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK o...

April 2021 70 pages

Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Drugs in Development, 2021

US$ 3,000.00

Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) - Drugs in Development, 2021 SUMMARY Alkaline Phosphatase (ALKP or Phosphomonoestera...

April 2021 35 pages

Allergic Asthma (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Allergic Asthma (Respiratory) - Drugs in Development, 2021 SUMMARY Allergic Asthma (Respiratory) - Drugs in Development, 2021 provides an overview of the Allergic Asthma pipeline landscape. The report...

April 2021 115 pages

Allergic Bronchopulmonary Aspergillosis (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Allergic Bronchopulmonary Aspergillosis (Infectious Disease) - Drugs in Development, 2021 SUMMARY Allergic Bronchopulmonary Aspergillosis (Infectious Disease) - Drugs in Development, 2021 provides an...

April 2021 35 pages

Allergic Rhino-Conjunctivitis (Ophthalmology) - Drugs in Development, 2021

US$ 2,000.00

Allergic Rhino-Conjunctivitis (Ophthalmology) - Drugs in Development, 2021 SUMMARY Allergic Rhino-Conjunctivitis (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Allergic Rhino...

April 2021 40 pages

Alopecia Areata (Dermatology) - Drugs in Development, 2021

US$ 2,000.00

Alopecia Areata (Dermatology) - Drugs in Development, 2021 SUMMARY Alopecia Areata (Dermatology) - Drugs in Development, 2021 provides an overview of the Alopecia Areata pipeline landscape. The report...

April 2021 60 pages

Alpha 1 Adrenergic Receptor (ADRA1) - Drugs in Development, 2021

US$ 3,000.00

Alpha 1 Adrenergic Receptor (ADRA1) - Drugs in Development, 2021 SUMMARY Alpha 1 Adrenergic Receptor (ADRA1) - Drugs in Development, 2021 provides in depth analysis on Alpha 1 Adrenergic Receptor (ADR...

April 2021 60 pages

Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1) - Drugs in Development, 2021

US$ 3,000.00

Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1) - Drugs in Development, 2021 SUMMARY Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or...

April 2021 60 pages

Alpha 1B Adrenergic Receptor (Alpha 1B Adrenoreceptor or ADRA1B) - Drugs in Development, 2021

US$ 3,000.00

Alpha 1B Adrenergic Receptor (Alpha 1B Adrenoreceptor or ADRA1B) - Drugs in Development, 2021 SUMMARY Alpha 1B Adrenergic Receptor (Alpha 1B Adrenoreceptor or ADRA1B) - Drugs in Development, 2021 prov...

April 2021 35 pages

Alpha 1D Adrenergic Receptor (Alpha 1A Adrenergic Receptor or Alpha 1D Adrenoreceptor or Alpha Adrenergic Receptor 1a or ADRA1D) - Drugs in Development, 2021

US$ 3,000.00

Alpha 1D Adrenergic Receptor (Alpha 1A Adrenergic Receptor or Alpha 1D Adrenoreceptor or Alpha Adrenergic Receptor 1a or ADRA1D) - Drugs in Development, 2021 SUMMARY Alpha 1D Adrenergic Receptor (Alph...

April 2021 30 pages

Alpha 2 Adrenergic Receptor (ADRA2) - Drugs in Development, 2021

US$ 3,000.00

Alpha 2 Adrenergic Receptor (ADRA2) - Drugs in Development, 2021 SUMMARY Alpha 2 Adrenergic Receptor (ADRA2) - Drugs in Development, 2021 provides in depth analysis on Alpha 2 Adrenergic Receptor (ADR...

April 2021 60 pages

Alpha Adrenergic Receptor (ADRA) - Drugs in Development, 2021

US$ 3,000.00

Alpha Adrenergic Receptor (ADRA) - Drugs in Development, 2021 SUMMARY Alpha Adrenergic Receptor (ADRA) - Drugs in Development, 2021 provides in depth analysis on Alpha Adrenergic Receptor (ADRA) targe...

April 2021 30 pages

Alport Syndrome (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Alport Syndrome (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Alport Syndrome (Genetic Disorders) - Drugs in Development, 2021 provides an overview of the Alport Syndrome pipeline landscape...

April 2021 35 pages

Amine Oxidase [Flavin Containing] A (Monoamine Oxidase Type A or MAOA or EC 1.4.3.4) - Drugs in Development, 2021

US$ 3,000.00

Amine Oxidase [Flavin Containing] A (Monoamine Oxidase Type A or MAOA or EC 1.4.3.4) - Drugs in Development, 2021 SUMMARY Amine Oxidase [Flavin Containing] A (Monoamine Oxidase Type A or MAOA or EC 1....

April 2021 35 pages

Amine Oxidase [Flavin Containing] B (Monoamine Oxidase Type B or MAOB or EC 1.4.3.4) - Drugs in Development, 2021

US$ 3,000.00

Amine Oxidase [Flavin Containing] B (Monoamine Oxidase Type B or MAOB or EC 1.4.3.4) - Drugs in Development, 2021 SUMMARY Amine Oxidase [Flavin Containing] B (Monoamine Oxidase Type B or MAOB or EC 1....

April 2021 55 pages

Amino Acid Metabolism Disorders (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Amino Acid Metabolism Disorders (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Amino Acid Metabolism Disorders (Genetic Disorders) - Drugs in Development, 2021 provides an overview of the Am...

April 2021 30 pages

Anal Fissure (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Anal Fissure (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Anal Fissure (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Anal Fissure pipeline landscape. The repor...

April 2021 30 pages

Anaplastic Large Cell Lymphoma (ALCL) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Anaplastic Large Cell Lymphoma (ALCL) (Oncology) - Drugs in Development, 2021 SUMMARY Anaplastic Large Cell Lymphoma (ALCL) (Oncology) - Drugs in Development, 2021 provides an overview of the Anaplast...

April 2021 115 pages

Anaplastic Thyroid Cancer (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Anaplastic Thyroid Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Anaplastic Thyroid Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Anaplastic Thyroid Cancer pipeli...

April 2021 65 pages

Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) - Drugs in Development, 2021

US$ 3,000.00

Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) - Drugs in Development, 2021 SUMMARY Androgen Receptor (Dihydrotestosterone Rec...

April 2021 160 pages

Androgen-Sensitive Prostate Cancer (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Androgen-Sensitive Prostate Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Androgen-Sensitive Prostate Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Androgen-Sensi...

April 2021 30 pages

Androgenic Alopecia (Dermatology) - Drugs in Development, 2021

US$ 2,000.00

Androgenic Alopecia (Dermatology) - Drugs in Development, 2021 SUMMARY Androgenic Alopecia (Dermatology) - Drugs in Development, 2021 provides an overview of the Androgenic Alopecia pipeline landscape...

April 2021 50 pages

Anemia of Chronic Disease (Hematological Disorders) - Drugs in Development, 2021

US$ 2,000.00

Anemia of Chronic Disease (Hematological Disorders) - Drugs in Development, 2021 SUMMARY Anemia of Chronic Disease (Hematological Disorders) - Drugs in Development, 2021 provides an overview of the An...

April 2021 30 pages

Angelman Syndrome (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Angelman Syndrome (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Angelman Syndrome (Genetic Disorders) - Drugs in Development, 2021 provides an overview of the Angelman Syndrome pipeline lan...

April 2021 50 pages

Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy (Oncology) - Drugs in Development, 2021 SUMMARY Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy (Oncolog...

April 2021 100 pages

Angiopoietin 2 (Ang 2 or ANGPT2) - Drugs in Development, 2021

US$ 3,000.00

Angiopoietin 2 (Ang 2 or ANGPT2) - Drugs in Development, 2021 SUMMARY Angiopoietin 2 (Ang 2 or ANGPT2) - Drugs in Development, 2021 provides in depth analysis on Angiopoietin 2 (Ang 2 or ANGPT2) targe...

April 2021 45 pages

Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3) - Drugs in Development, 2021

US$ 3,000.00

Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3) - Drugs in Development, 2021 SUMMARY Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin L...

April 2021 35 pages

Angiosarcoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Angiosarcoma (Oncology) - Drugs in Development, 2021 SUMMARY Angiosarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Angiosarcoma pipeline landscape. The report provides compr...

April 2021 50 pages

Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) - Drugs in Development, 2021

US$ 3,000.00

Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) - Drugs in Development, 2021 SUMMARY Angiotensin Converting Enzyme (Dipeptidyl...

April 2021 40 pages

Anorexia Nervosa (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Anorexia Nervosa (Central Nervous System) - Drugs in Development, 2021 SUMMARY Anorexia Nervosa (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Anorexia Nervosa pipel...

April 2021 35 pages

Anterior Uveitis (Ophthalmology) - Drugs in Development, 2021

US$ 2,000.00

Anterior Uveitis (Ophthalmology) - Drugs in Development, 2021 SUMMARY Anterior Uveitis (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Anterior Uveitis pipeline landscape. The...

April 2021 45 pages

Filters

Clear all